Colon cancer metastatic

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
7 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 3 substances
RAF/BRAF inhibitor 1 substance
Unknown / small molecule 1 substance
Antimetabolite 1 substance
Platinum compound 1 substance
Phase II: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

2 trials
  • Agenus Inc. Commercial
    BALSTILIMAB; BOTENSILIMAB; REGORAFENIB; TRIFLURIDINE, TIPIRACIL
    2022-502065-23-00 4 countries 2023 n=102
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    CAPECITABINE; DOSTARLIMAB; OXALIPLATIN
    2024-513441-36-00 3 countries 2024 n=170
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Agenus Inc. Commercial 1 Phase II 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase II 1
New trials by year
2023
1
2024
1
← All indication landscapes